Fondaparinux: Indications, Dosing, Contraindications, and Monitoring
Fondaparinux is a synthetic pentasaccharide Factor Xa inhibitor indicated for VTE prophylaxis and treatment, with weight-based dosing for treatment and fixed 2.5 mg daily dosing for prophylaxis, contraindicated in severe renal impairment (CrCl <30 mL/min) and requiring no routine coagulation monitoring. 1
Indications
VTE Prophylaxis
- Hospitalized medical patients with acute illness (heart failure, respiratory insufficiency, infectious/inflammatory diseases) 2, 3
- Surgical patients: Hip fracture surgery (including extended prophylaxis up to 24 additional days), hip replacement, knee replacement, and abdominal surgery 2, 1
- Cancer patients: Hospitalized patients with active malignancy 2, 3
VTE Treatment
- Acute DVT and pulmonary embolism when administered in conjunction with warfarin 4, 1
- Superficial vein thrombosis at increased risk of progression to DVT/PE 5
Other Indications
- Acute coronary syndromes (fixed 2.5 mg daily dose) 6, 7
- Alternative anticoagulant in heparin-induced thrombocytopenia (HIT) - fondaparinux has low affinity for PF4 and does not cross-react with HIT antibodies 6
Dosing Regimens
Prophylaxis Dosing
Fixed dose: 2.5 mg subcutaneously once daily 2, 6, 1
- Timing: Initial dose should be given no earlier than 6-8 hours after surgery once hemostasis is established 2, 1
- Duration:
Treatment Dosing (Weight-Based)
Administered subcutaneously once daily 6, 4, 1:
- <50 kg: 5 mg once daily
- 50-100 kg: 7.5 mg once daily
- >100 kg: 10 mg once daily
Duration: Continue for at least 5 days and until INR 2-3 achieved with warfarin 2, 1
Pediatric Dosing
Starting dose: 0.1 mg/kg once daily for children aged 1-17 years 8
- Target peak concentration: 0.5-1.0 mg/L at 4 hours post-dose
- 88% of children achieve target without dose adjustment 8
Special Populations Dosing Adjustments
Moderate renal impairment (CrCl 30-50 mL/min):
- For prophylaxis: Reduce dose by 50% (1.25 mg daily) OR use low-dose heparin instead 6, 3
- Use with caution in patients with weight <50 kg or age >75 years 3
No dose adjustment needed for mild-to-moderate hepatic impairment 1
Contraindications
Absolute Contraindications 1
- Severe renal impairment (CrCl <30 mL/min) - fondaparinux is renally excreted unchanged
- Active major bleeding
- Bacterial endocarditis
- Thrombocytopenia associated with positive in vitro anti-platelet antibody in presence of fondaparinux
- Body weight <50 kg (for VTE prophylaxis only)
- History of serious hypersensitivity reaction (angioedema, anaphylaxis) to fondaparinux
Relative Contraindications/High-Risk Situations 3
- Recent CNS bleed or intracranial/spinal lesion at high bleeding risk
- Thrombocytopenia (platelets <50,000/mcL)
- Severe platelet dysfunction
- Recent major operation at high bleeding risk
- Underlying hemorrhagic coagulopathy
- Spinal anesthesia/lumbar puncture within specific timeframes
Monitoring Requirements
Routine Monitoring
No routine coagulation monitoring is recommended - fondaparinux produces predictable anticoagulant response with linear pharmacokinetics 6, 1
Recommended periodic monitoring 3:
- Complete blood count including platelet count every 2-3 days up to day 14, then every 2 weeks
- Serum creatinine level
- Stool occult blood tests
- Hemoglobin/hematocrit
Important: Unlike heparin/LMWH, platelet count monitoring for HIT is not indicated due to minimal HIT risk 6, 9
When Laboratory Monitoring May Be Useful
Anti-Factor Xa assay (fondaparinux-specific calibration required) 6, 8:
- Prophylactic dosing: Peak steady-state 0.39-0.50 mg/L (at 3 hours post-dose) 6
- Therapeutic dosing: Peak steady-state 1.20-1.26 mg/L (at 3 hours post-dose) 6
- Pediatric target: 0.5-1.0 mg/L at 4 hours post-dose 8
Consider monitoring in:
- Severe renal failure (though contraindicated for treatment)
- Pregnancy 8
- Children 8
- Obese patients 10
- Patients with moderate renal impairment receiving reduced doses
Note: Fondaparinux does not affect routine coagulation tests (PT, aPTT) at therapeutic doses, though aPTT prolongation can occur at higher doses 8
Pharmacokinetic Properties
- Bioavailability: Nearly 100% subcutaneously 6, 11
- Half-life: 17 hours (young), 21 hours (elderly) 6
- Time to peak: 2-3 hours 6
- Steady state: Reached after 3rd-4th once-daily dose 6
- Excretion: Unchanged in urine 6
- Anticoagulant effect persistence: 2-4 days in normal renal function 8
Management of Bleeding
No specific antidote exists - fondaparinux does not bind to protamine sulfate 6, 1
Management options:
- Recombinant factor VIIa may be effective for uncontrollable bleeding 6
- Supportive care and blood product transfusion as needed
- Consider hemodialysis in severe cases with renal failure 12
Key Clinical Pearls
Advantages over heparins:
- No HIT risk requiring platelet monitoring 6
- Once-daily dosing due to long half-life 6
- Predictable pharmacokinetics without routine monitoring 6
- Lower risk of osteopenia compared to heparin/LMWH 6
- Successfully used in patients with skin reactions to multiple LMWHs 6
Critical timing consideration: The 6-8 hour post-operative delay before first dose is essential - earlier administration significantly increases major bleeding risk 1
Neuraxial anesthesia warning: Spinal/epidural hematomas can occur; optimal timing between fondaparinux administration and neuraxial procedures is unknown 1
Not for PCI support: Fondaparinux should not be used to support percutaneous coronary intervention due to catheter thrombosis risk 7